CEO of Simulations Plus, Shawn O’Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on ...

Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...

BTIG analyst Marvin Fong raised the firm’s price target on RealReal (REAL) to $5.50 from $4 and keeps a Buy rating on the shares. The firm ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...

BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a ...

Energy and Infrastructure Transition Analyst Lewis holds a virtual meeting with management on November 22 hosted by BTIG. Don't Miss out on Research Tools: Discover the latest stocks recommended by ...

Donald Trump has been somewhat cagey about his economic plans — especially tariffs — since voters elected him president. That ...

Donald Trump has been somewhat cagey about his economic plans — especially tariffs — since voters elected him president. That ...

Conservative media personality Megyn Kelly on Monday blasted “Morning Joe” hosts Joe Scarborough and Mika Brzezinski, calling ...

Shares of Birkenstock Holding plc (NYSE:BIRK – Get Free Report) have received an average rating of “Moderate Buy” from the ...

Shares of Aclaris Therapeutics (NASDAQ:ACRS) soared 60% Tuesday, the day after the company announced it was licensing two ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...